(1)
In general
In carrying out subsection (a) of this section, the Director of the Institute shall conduct or support research to expand the understanding of the cause of, and to find a cure for, prostate cancer. Activities under such subsection shall provide for an expansion and intensification of the conduct and support of—
(A)
basic research concerning the etiology and causes of prostate cancer;
(B)
clinical research and related activities concerning the causes, prevention, detection and treatment of prostate cancer;
(C)
prevention and control and early detection programs with respect to prostate cancer in accordance with section
285a–1 of this title, particularly as it relates to intensifying research on the role of prostate specific antigen for the screening and early detection of prostate cancer;
(D)
an Inter-Institute Task Force, under the direction of the Director of the Institute, to provide coordination between relevant National Institutes of Health components of research efforts on prostate cancer;
(E)
control programs with respect to prostate cancer in accordance with section
285a–1 of this title;
(F)
information and education programs with respect to prostate cancer in accordance with section
285a–2 of this title; and
(G)
research and demonstration centers with respect to prostate cancer in accordance with section
285a–3 of this title, including the development and operation of centers for prostate cancer research to bring together basic and clinical, biomedical and behavioral scientists to conduct basic, clinical, epidemiological, psychosocial, prevention and control, treatment, research, and related activities on prostate cancer.
Not less than six centers shall be operated under subparagraph (G). Activities of such centers should include supporting new and innovative research and training programs for new researchers. Such centers shall give priority to expediting the transfer of research advances to clinical applications.